Dergiler / Turkish Journal of Medical Sciences / 2021 / Cilt: 51 - Sayı: 5

Central nervous system involvement in patients with acute myeloid leukemia

Sayfa
2351–2356
Yayın Tarihi
2022-11-05
DOI
—
🏛️Bu makalenin bibliyografik verileri ve tam metin bağlantısı DergiPark üzerinden sağlanmıştır.
DergiPark Kaydı ↗
✨

Yapay Zeka Hızlı Bakış & Çıkarımlar

AI Insight
⚡ TL;DR(1 Cümlede Hızlı Çıkarım)

Younger age and extramedullary involvement at diagnosis are risk factors for CNS involvement.Keywords: Acute myeloid leukemia, central nervous system involvement, risk factors

📌 3 Maddede Bu Makale

🎯
Amaç & Hipotez:Background/aim: To evaluate the incidence, clinical features, risk factors, and prognosis of central nervous system (CNS) involvement in patients with acute myeloid leukemia (AML).
📊
Temel Bulgular & Veri:Materials and methods: All AML patients who were admitted to Hacettepe University hospital between 2000 and 2021 were evaluated.
💡
Sonuç & Katkı:Younger age and extramedullary involvement at diagnosis are risk factors for CNS involvement.Keywords: Acute myeloid leukemia, central nervous system involvement, risk factors
🔬Tür:Araştırma Makalesi
📍Kapsam:2000 Verileri
⚙️Değişkenler:Alan Parametreleri

Abstract

Background/aim: To evaluate the incidence, clinical features, risk factors, and prognosis of central nervous system (CNS) involvement in patients with acute myeloid leukemia (AML). Materials and methods: All AML patients who were admitted to Hacettepe University hospital between 2000 and 2021 were evaluated. The medical records of 548 AML cases were retrospectively analyzed. Results: The frequency of CNS involvement was 2.4% (n = 13) at diagnosis and 4.6% (n = 25) at diagnosis or during follow-up. Parenchymal involvement was seen in 5 patients, leptomeningeal involvement was seen in 11 patients. Three patients had both leptomeningeal and parenchymal involvements, and 6 patients had optic nerve or ocular involvement. In univariate analysis, younger age and extramedullary involvement at diagnosis were associated with CNS disease at diagnosis, and extramedullary involvement at diagnosis was associated with CNS disease during follow-up. In multivariate analysis; younger age and extramedullary involvement at diagnosis were associated with CNS disease at diagnosis and during follow-up respectively. Median overall survival was 5.4 months in patients with CNS disease at diagnosis and 16.9 months in patients with CNS disease during follow-up and 16.2 months in patients with no CNS disease. Conclusion: CNS disease is a rare complication of AML. Younger age and extramedullary involvement at diagnosis are risk factors for CNS involvement.Keywords: Acute myeloid leukemia, central nervous system involvement, risk factors

🔖

Bu Makaleye Atıf Yap

BÜYÜKAŞIK, Y., GÖKER, H., YAŞAR, H. A., ÇINAR, O. E., KÖYLÜ, N. Y., BARIŞTA, İ. (2022). Central nervous system involvement in patients with acute myeloid leukemia. Turkish Journal of Medical Sciences, Cilt: 51 - Sayı: 5, 2351–2356. https://ajindex.com/articles/609484

📄 Tam Metin PDF Okuyucu

📄

PDF görüntüleyici hazırlanıyor...

Kaynakça (12)

  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA: a Cancer Journal for Clinicians 2019
  2. 69 (1): 7-34. doi:10.3322/ caac.21551 2. Castagnola C, Nozza A, Corso A, Bernasconi C. The value of combination therapy in adult acute myeloid leukemia with central nervous system involvement. Haematologica 1997
  3. 82 (5): 577-580. 3. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood 2017
  4. 129 (4): 424-447. doi:10.1182/blood-2016-08-733196 4. Cassileth PA, Sylvester LS, Bennett JM, Begg CB. High peripheral blast count in adult acute myelogenous leukemia is a primary risk factor for CNS leukemia. Journal of Clinical Oncology 1988
  5. 6 (3): 495-498. doi:10.1200/JCO.1988.6.3.495 5. Holmes R, Keating MJ, Cork A, Broach Y, Trujillo J et al. A unique pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 1985
  6. 65 (5): 1071-1078 6. Shihadeh F, Reed V, Faderl S, Medeiros LJ, Mazloom A et al. Cytogenetic profile of patients with acute myeloid leukemia and central nervous system disease. Cancer 2012
  7. 118 (1): 112- 117. doi:10.1002/cncr.26253 7. Rozovski U, Ohanian M, Ravandi F, Garcia-Manero G, Faderl S et al. Incidence of and risk factors for involvement of the central nervous system in acute myeloid leukemia. Leukemia & Lymphoma 2015
  8. 56 (5): 1392-1397. doi:10.3109/10428194.2014.953148 8. Alakel N, Stolzel F, Mohr B, Kramer M, Oelschlagel U et al. Symptomatic central nervous system involvement in adult patients with acute myeloid leukemia. Cancer Management and Research 2017
  9. doi:10.2147/CMAR.S125259 9. Jabbour E, Guastad Daver N, Short NJ, Huang X, Chen HC et al. Factors associated with risk of central nervous system relapse in patients with non-core binding factor acute myeloid leukemia. American Journal of Hematology 2017
  10. 92 (9): 924- 928. doi:10.1002/ajh.24799 10. Seymour JF, Pierce SA, Kantarjian HM, Keating MJ, Estey EH. Investigation of karyotypic, morphologic and clinical features in patients with acute myeloid leukemia blast cells expressing the neural cell adhesion molecule (CD56). Leukemia 1994
  11. 8 (5): 823-826. 11. Chang H, Brandwein J, Yi QL, Chun K, Patterson B et al. Extramedullary infiltrates of AML are associated with CD56 expression, 11q23 abnormalities and inferior clinical outcome. Leukemia Research 2004
  12. 28 (10): 1007-1011. doi:10.1016/j. leukres.2004.01.006